Download
Download by
Scanning QR Code
No matches yet
Please check network settings and try again Refresh
Loading
Futu Hot Stocks
    Latest News
    History record delete
      Quotes All >
      News All >
      Help All >

      • Download app

        Download app

      +
      Congratulations
      You've successfully got advanced quotes worth 5000 HKD
      Download APP >>
      Quotes
      Detailed Quotes
      Company Overview
      Company ProfileCompany Executives
      Financial Analysis
      Main CompositionKey IndicatorsFinancial Statement
      Multi-dimentional Analyses
      Company Valuation Capital Tracking Short Selling Data
      Futubull > Quotes > 603456 Zhejiang Jiuzhou Pharmaceutical > Financial Statement > Income statement
      603456 Zhejiang Jiuzhou Pharmaceutical
      29.560
      +0.430+1.48%
      Income statement Balance sheet Cash flow
      YOY
      Do not show
      Hide blank lines
      (Q3)2023/03/31(FY)2022/12/31(Q9)2022/09/30(Q6)2022/06/30
      Total operating revenue
      27.49% 1.75B 34.01% 5.45B 45.55% 4.37B 58.15% 2.95B
      Operating revenue
      27.49% 1.75B 34.01% 5.45B 45.55% 4.37B 58.15% 2.95B
      Other operating revenue
      -- -- 9.89% 264.29M -- -- 55.80% 132.61M
      Total operating cost
      21.45% 1.36B 28.48% 4.28B 39.13% 3.44B 49.95% 2.34B
      Operating cost
      24.46% 1.11B 31.33% 3.56B 40.37% 2.85B 50.86% 1.92B
      Operating tax surcharges
      53.89% 11.98M 34.87% 35.77M 27.71% 24.18M 23.12% 15.46M
      Operating expense
      15.67% 22.91M 17.43% 57.5M 38.29% 51.27M 60.33% 38.69M
      Administration expense
      3.96% 128.47M 27.22% 429.15M 53.86% 375.35M 66.96% 262.6M
      Financial expense
      -37.02% 7.88M -331.67% -86.17M -659.51% -92.99M -443.69% -56.16M
      -Interest expense (Financial expense)
      -43.63% 4.64M -10.02% 22.38M 2.29% 19.3M 8.39% 14.87M
      -Interest Income (Financial expense)
      -537.82% -6.04M -72.06% -13.2M -42.83% -8.31M -9.83% -4.48M
      Research and development
      22.71% 78.77M 65.77% 287.38M 86.24% 227.41M 102.26% 166.8M
      Credit Impairment Loss
      -11,421.39% -16.34M 165.38% 5.37M 172.60% 5.33M -249.58% -12.22M
      Asset Impairment Loss
      -82.19% -37.01M -16.76% -59.33M -75.62% -44.48M -197.07% -43.77M
      Other net revenue
      -981.54% -46.67M -343.52% -55.74M -440.66% -58.91M -323.89% -54.61M
      Fair value change income
      365.00% 7.13M -2,433.50% -35.22M -803.15% -59.74M -913.94% -26.25M
      Invest income
      -148.89% -6.52M -96.61% 2.07M -54.72% 20.28M -49.85% 15.78M
      -Including: Investment income associates
      -495.82% -1.63M -95.09% 58.89K -90.32% 158.96K -88.60% 145.7K
      Asset deal income
      36.69% -123.26K 40.07% -4.79M 47.35% -2.62M 39.29% -2.18M
      Other revenue
      14.49% 6.19M 19.60% 36.15M 33.17% 22.31M 21.69% 14.03M
      Operating profit
      37.83% 349.45M 47.01% 1.11B 59.14% 873.92M 68.81% 555.81M
      Add:Non operating Income
      377.65% 297.63K 329.75% 3.14M 1,020.90% 1.69M 1,065.33% 1.56M
      Less:Non operating expense
      -84.33% 272.12K -24.85% 7.23M -21.23% 4.03M -49.04% 3.42M
      Total profit
      38.76% 349.48M 48.22% 1.1B 60.16% 871.58M 71.68% 553.95M
      Less:Income tax cost
      57.39% 70.02M 65.72% 183.27M 83.75% 130.1M 80.40% 85.82M
      Net profit
      34.76% 279.46M 45.16% 920.55M 56.63% 741.48M 70.17% 468.13M
      Net profit from continuing operation
      34.76% 279.46M 45.16% 920.55M 56.63% 741.48M 70.17% 468.13M
      Less:Minority Profit
      -185.65% -1.24M -248.85% -372.09K -771.65% -1.75M -73.95% 67.85K
      Net profit of parent company owners
      35.07% 280.69M 45.28% 920.92M 57.09% 743.23M 70.31% 468.06M
      Earning per share
      Basic earning per share
      28.00% 0.32 44.16% 1.11 57.89% 0.9 69.70% 0.56
      Diluted earning per share
      28.00% 0.32 46.05% 1.11 56.14% 0.89 69.70% 0.56
      Other composite income
      257.72% 1.42M 190.25% 929.42K 355.20% 3.32M 61.64% -515.12K
      Other composite income of parent company owners
      257.72% 1.42M 196.00% 929.42K 376.32% 3.32M 58.57% -515.12K
      Total composite income
      36.03% 280.87M 45.55% 921.48M 57.77% 744.8M 70.82% 467.61M
      Total composite income of parent company owners
      36.34% 282.11M 45.65% 921.85M 58.19% 746.55M 70.89% 467.55M
      Total composite income of minority owners
      -185.65% -1.24M -297.64% -372.09K -1,185.73% -1.75M -57.89% 67.85K
      Currency Unit
      CNYCNYCNYCNY
      Accounting Standards
      CAS (2007)CAS (2007)CAS (2007)CAS (2007)
      Audit Opinions
      --Unqualified opinion----
      Auditor
      --Tianjian Certified Public Accountants (Special General Partnership)----

      Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

      The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%

      Company Overview More
      R&D and production of chemical raw materials, pharmaceutical intermediates, and pharmaceutical preparations (operated under license); technical development and technical services for innovative pharmaceuticals and biotechnology; R&D and sales of new drugs, pharmaceutical intermediates and APIs (operated under license); manufacture, sale of chemical raw materials (excluding hazardous chemicals and easy-to-make drugs), machinery and equipment. (For projects requiring approval according to law, business activities can only be carried out after approval by relevant departments) ##
      CEO： --
      Market： --
      Listing Date： 10/10/2014
      Futu Hot List
      CNHKUS
      SearchNews
      SymbolLatest price%Chg

      Loading...

      Watchlist
      Back to the Top